KA/EN
Register
Medicines reference
Search
Search
Active substance

Atenolol

Favourites

Beta-1 selective adrenoceptor blocker. Registered in Georgia: 5 human medicines. Forms: tablet.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Atenolol
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.2–1.5 mg/kg
off-label
 Dog Tachyarrhythmia By mouth 2 times daily
MSD Vet Manual 2024
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Cardiac Medications of Dogs and Cats (table)
MSD/Merck Veterinary Manual, 2024
6.25–12.5 mg per animal
off-label
 Cat Tachyarrhythmia By mouth 2 times daily
MSD Vet Manual 2024
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Cardiac Medications of Dogs and Cats (table)
MSD/Merck Veterinary Manual, 2024
6.25 mg per animal
off-label
 Cat Hypertrophic Cardiomyopathy By mouth 2 times daily
ACVIM feline cardiomyopathy
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats
Journal of Veterinary Internal Medicine, 2020
Before use

Safety information

Known Contraindications

  • Critical
    Atenolol is contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure.
    Sources: FDA
  • Critical
    Heart failure: the label contraindicates atenolol in overt (decompensated) heart failure. In dogs and cats with stable congestive heart failure or dilated cardiomyopathy, start with a low dose and increase it slowly.
    Sources: FDA · MSD Vet Manual
  • Critical
    Known hypersensitivity to atenolol or any product component is a contraindication.
    Sources: FDA
  • Warning
    undergoes little or no metabolism by the liver, and the absorbed portion is eliminated primarily by renal excretion.
    Sources: FDA
  • Warning
    Abrupt discontinuation should be avoided; if cessation is indicated, titrating down gradually is recommended.
    Sources: MSD Vet Manual
  • Caution
    Asthma or airway disease: atenolol is beta-1 selective, so its bronchospasm risk is lower than that of propranolol, which MSD says should be avoided in dogs and cats with primary respiratory disease. Selectivity falls at higher doses: use with caution.
    Sources: MSD Vet Manual
  • Caution
    Adverse effects include myocardial depression, bradycardia (sinus and AV block), and hypotension.
    Sources: MSD Vet Manual

Known Drug Interactions

  • Contraindicated Atenolol + Xylometazoline
    Do not combine xylometazoline with beta blockers because additive cardiovascular effects may occur.
    Recommendation: Do not administer concurrently.
  • Minor warning Pimobendan + Atenolol
    Beta-adrenergic blockers such as propranolol or atenolol and calcium-channel blockers such as verapamil or diltiazem can reduce the positive inotropic effect of pimobendan.
    Recommendation: Monitor clinical response.
    Sources: Vetmedin SPC
  • Minor warning Atenolol + Methimazole
    A reduction in dose of certain drugs (β-adrenergic blocking agents, digitalis glycosides, and theophylline) may be needed when the patient becomes euthyroid.
    Recommendation: Reassess the dose once euthyroidism is achieved.
    Sources: FDA
Latin name
Atenolol
Georgian name
ატენოლოლი
Authorisation status
Human medicine, cascade use
No veterinary authorisation was found in any register checked. Veterinary use is off-label, under the prescribing cascade.
Registered in Georgia
5 of 5 forms
Products
Atenolol-Denk, Atenolol Borisov, Atenolol Gama, Atenolol Sopharma
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration5

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Atenolol-Denk 50 mg, Tablet

film-coated tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label oral atenolol as veterinary-selected beta-1 blockade for selected canine tachyarrhythmias or clinically important sympathetic rate control
6.3/10
Situational / acceptable
vetman assessment

Atenolol-Denk

50 mg, film-coated tablet, human medicine
Assessed clinical scopeDog · Off-label oral atenolol as veterinary-selected beta-1 blockade for selected canine tachyarrhythmias or clinically important sympathetic rate control · By mouth
Care settingSpecialist-guided or closely monitored outpatient cardiac treatment after ECG, blood pressure and haemodynamic assessment, with slow titration and scheduled reassessment
vetman score 6.3/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-038897 · Verified on 16 Oct 2026 Off-label use

A situational canine beta-1 blocker with recognised rate-control use and important disease-specific evidence limits. Verified 25 and 50 mg units are workable for selected medium or large dogs, but smaller or fine-titrated doses require a more suitable formulation.

Regulatory and scientific credibility6.5/10

The exact human tablet has sourced current registrations in Georgia and EU/EEA, with an identifiable manufacturer, strength and verified split rule. It has no veterinary authorisation, no checked UK or US exact trade-name registration, and animal use is off-label.

Clinical efficacy6.5/10

Atenolol produces measurable beta-1 blockade and remains a recognised veterinary class-II option, but effect depends on disease and regimen. A randomized Boxer trial found atenolol alone ineffective while mexiletine-atenolol helped; severe subaortic-stenosis cohorts found no survival benefit, and controlled pharmacodynamics support dosing more often than once daily for sustained blockade.

Safety and tolerability6.0/10

Predictable beta blockade is clinically useful but can cause bradycardia, hypotension, AV block, exercise intolerance or worsening low-output and decompensated heart failure. These exact human tablets lack target-animal safety dossiers; renal clearance, bronchospasm risk, metabolic masking and interacting cardiac drugs require selection and monitoring.

Clinical practicality6.0/10

The scored 50 mg tablet provides verified 25 mg or 50 mg units, covering selected medium and large dogs better than a whole-only presentation. It still cannot support small-dog or fine dose adjustment, and twice-daily monitored titration remains necessary.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in clinically important sinus bradycardia, sick-sinus syndrome or second- or third-degree AV block without pacing; confirm rhythm before treatment.
  • Do not initiate during cardiogenic shock, acute decompensated heart failure or other unstable low-output states. Stabilise first and use only after an individual haemodynamic assessment.
  • Diltiazem, verapamil, digoxin, amiodarone, sotalol and other rate-slowing or negative-inotropic drugs can add bradycardia, AV block, hypotension or contractility depression; combine only with ECG and haemodynamic oversight.
  • Atenolol is substantially renally eliminated. Review kidney function, hydration and concurrent renally cleared drugs, and reconsider dose or interval if clearance is reduced.
  • Beta-1 selectivity is not absolute. Use cautiously in bronchospastic disease and monitor for new cough, wheeze or respiratory effort, especially at higher exposure.
  • Beta blockade may mask tachycardia from hypoglycaemia or hyperthyroidism and can alter insulin response. Monitor vulnerable diabetic, fasting, neonatal or endocrine patients rather than relying on heart rate alone.
  • Start low, titrate to the documented rhythm or haemodynamic target, and monitor pulse, blood pressure, ECG, perfusion, exercise tolerance and heart-failure signs. Do not stop chronic treatment abruptly; taper under veterinary direction.
  • This exact 50 mg tablet is verified only to a 25 mg half. Do not estimate a smaller dog or feline dose from an unmeasured fraction of crushed powder; use an accurately measurable lower strength or validated patient-specific compound.
Assessment sources
  1. Atenolol market audit2026
  2. FDA 20242024
  3. MSD Vet Manual 20242024
  4. ACVIM 20182018
  5. Canine atenolol duration RCT2019
  6. Boxer antiarrhythmic RCT2002
  7. Canine subaortic stenosis outcome2014
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label oral atenolol for selected feline tachyarrhythmias or severe dynamic left-ventricular outflow obstruction; not routine treatment of asymptomatic HCM
5.3/10
Weak evidence support
vetman assessment

Atenolol-Denk

50 mg, film-coated tablet, human medicine
Assessed clinical scopeCat · Off-label oral atenolol for selected feline tachyarrhythmias or severe dynamic left-ventricular outflow obstruction; not routine treatment of asymptomatic HCM · By mouth
Care settingSpecialist-guided or closely monitored outpatient cardiac treatment after ECG, blood pressure and haemodynamic assessment, with slow titration and scheduled reassessment
vetman score 5.3/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-038897 · Verified on 16 Oct 2026 Off-label use

The ingredient has a selective feline role, but this human tablet is a poor dose-delivery match: its smallest verified 25 mg unit is two to four times the usual 6.25-12.5 mg feline dose. Do not treat incidental asymptomatic HCM routinely or improvise an unmeasured powder fraction.

Regulatory and scientific credibility6.5/10

The exact human tablet has sourced current registrations in Georgia and EU/EEA, with an identifiable manufacturer, strength and verified split rule. It has no veterinary authorisation, no checked UK or US exact trade-name registration, and animal use is off-label.

Clinical efficacy6.0/10

Atenolol reliably lowers heart rate and dynamic outflow velocity in selected cats, and consensus allows it for severe DLVOTO or certain arrhythmias. Evidence does not support routine asymptomatic HCM treatment: a five-year cohort found no survival benefit, and the guideline rates key recommendations as low-level evidence.

Safety and tolerability6.0/10

Predictable beta blockade is clinically useful but can cause bradycardia, hypotension, AV block, exercise intolerance or worsening low-output and decompensated heart failure. These exact human tablets lack target-animal safety dossiers; renal clearance, bronchospasm risk, metabolic masking and interacting cardiac drugs require selection and monitoring.

Clinical practicality1.0/10

The usual sourced feline dose is 6.25-12.5 mg per cat, but the smallest verified unit from this presentation is 25 mg. Crushing does not make informal powder division accurate; a lower-strength or validated patient-specific compound is normally required.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in clinically important sinus bradycardia, sick-sinus syndrome or second- or third-degree AV block without pacing; confirm rhythm before treatment.
  • Do not initiate during cardiogenic shock, acute decompensated heart failure or other unstable low-output states. Stabilise first and use only after an individual haemodynamic assessment.
  • Diltiazem, verapamil, digoxin, amiodarone, sotalol and other rate-slowing or negative-inotropic drugs can add bradycardia, AV block, hypotension or contractility depression; combine only with ECG and haemodynamic oversight.
  • Atenolol is substantially renally eliminated. Review kidney function, hydration and concurrent renally cleared drugs, and reconsider dose or interval if clearance is reduced.
  • Beta-1 selectivity is not absolute. Use cautiously in bronchospastic disease and monitor for new cough, wheeze or respiratory effort, especially at higher exposure.
  • Beta blockade may mask tachycardia from hypoglycaemia or hyperthyroidism and can alter insulin response. Monitor vulnerable diabetic, fasting, neonatal or endocrine patients rather than relying on heart rate alone.
  • Start low, titrate to the documented rhythm or haemodynamic target, and monitor pulse, blood pressure, ECG, perfusion, exercise tolerance and heart-failure signs. Do not stop chronic treatment abruptly; taper under veterinary direction.
  • This exact 50 mg tablet is verified only to a 25 mg half. Do not estimate a smaller dog or feline dose from an unmeasured fraction of crushed powder; use an accurately measurable lower strength or validated patient-specific compound.
Assessment sources
  1. Atenolol market audit2026
  2. FDA 20242024
  3. MSD Vet Manual 20242024
  4. ACVIM 20182018
  5. ACVIM feline cardiomyopathy2020
  6. Feline HCM five-year outcome2013
  7. Feline HCM physiologic response2015
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Atenolol50 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Denk Pharma · Germany
Registration
Georgia Yes, human
In force until 22 Aug 2028
Human (Ministry of Health, RAMA)
In the register: ატენოლოლ-დენკი 50 მგ, აბი
№ რ-038897
Verified on: 16 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Atenolol Borisov 50 mg, Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label oral atenolol as veterinary-selected beta-1 blockade for selected canine tachyarrhythmias or clinically important sympathetic rate control
6.1/10
Situational / acceptable
vetman assessment

Atenolol Borisov

50 mg, tablet, human medicine
Assessed clinical scopeDog · Off-label oral atenolol as veterinary-selected beta-1 blockade for selected canine tachyarrhythmias or clinically important sympathetic rate control · By mouth
Care settingSpecialist-guided or closely monitored outpatient cardiac treatment after ECG, blood pressure and haemodynamic assessment, with slow titration and scheduled reassessment
vetman score 6.1/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-040566 · Verified on 16 Oct 2026 Off-label use

A situational canine beta-1 blocker with recognised rate-control use and important disease-specific evidence limits. Verified 25 and 50 mg units are workable for selected medium or large dogs, but smaller or fine-titrated doses require a more suitable formulation.

Regulatory and scientific credibility6.0/10

The exact human tablet has a sourced current Georgian registration, identifiable manufacturer, strength and verified split rule, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Clinical efficacy6.5/10

Atenolol produces measurable beta-1 blockade and remains a recognised veterinary class-II option, but effect depends on disease and regimen. A randomized Boxer trial found atenolol alone ineffective while mexiletine-atenolol helped; severe subaortic-stenosis cohorts found no survival benefit, and controlled pharmacodynamics support dosing more often than once daily for sustained blockade.

Safety and tolerability6.0/10

Predictable beta blockade is clinically useful but can cause bradycardia, hypotension, AV block, exercise intolerance or worsening low-output and decompensated heart failure. These exact human tablets lack target-animal safety dossiers; renal clearance, bronchospasm risk, metabolic masking and interacting cardiac drugs require selection and monitoring.

Clinical practicality6.0/10

The scored 50 mg tablet provides verified 25 mg or 50 mg units, covering selected medium and large dogs better than a whole-only presentation. It still cannot support small-dog or fine dose adjustment, and twice-daily monitored titration remains necessary.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in clinically important sinus bradycardia, sick-sinus syndrome or second- or third-degree AV block without pacing; confirm rhythm before treatment.
  • Do not initiate during cardiogenic shock, acute decompensated heart failure or other unstable low-output states. Stabilise first and use only after an individual haemodynamic assessment.
  • Diltiazem, verapamil, digoxin, amiodarone, sotalol and other rate-slowing or negative-inotropic drugs can add bradycardia, AV block, hypotension or contractility depression; combine only with ECG and haemodynamic oversight.
  • Atenolol is substantially renally eliminated. Review kidney function, hydration and concurrent renally cleared drugs, and reconsider dose or interval if clearance is reduced.
  • Beta-1 selectivity is not absolute. Use cautiously in bronchospastic disease and monitor for new cough, wheeze or respiratory effort, especially at higher exposure.
  • Beta blockade may mask tachycardia from hypoglycaemia or hyperthyroidism and can alter insulin response. Monitor vulnerable diabetic, fasting, neonatal or endocrine patients rather than relying on heart rate alone.
  • Start low, titrate to the documented rhythm or haemodynamic target, and monitor pulse, blood pressure, ECG, perfusion, exercise tolerance and heart-failure signs. Do not stop chronic treatment abruptly; taper under veterinary direction.
  • This exact 50 mg tablet is verified only to a 25 mg half. Do not estimate a smaller dog or feline dose from an unmeasured fraction of crushed powder; use an accurately measurable lower strength or validated patient-specific compound.
Assessment sources
  1. Atenolol market audit2026
  2. FDA 20242024
  3. MSD Vet Manual 20242024
  4. ACVIM 20182018
  5. Canine atenolol duration RCT2019
  6. Boxer antiarrhythmic RCT2002
  7. Canine subaortic stenosis outcome2014
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label oral atenolol for selected feline tachyarrhythmias or severe dynamic left-ventricular outflow obstruction; not routine treatment of asymptomatic HCM
5.2/10
Weak evidence support
vetman assessment

Atenolol Borisov

50 mg, tablet, human medicine
Assessed clinical scopeCat · Off-label oral atenolol for selected feline tachyarrhythmias or severe dynamic left-ventricular outflow obstruction; not routine treatment of asymptomatic HCM · By mouth
Care settingSpecialist-guided or closely monitored outpatient cardiac treatment after ECG, blood pressure and haemodynamic assessment, with slow titration and scheduled reassessment
vetman score 5.2/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-040566 · Verified on 16 Oct 2026 Off-label use

The ingredient has a selective feline role, but this human tablet is a poor dose-delivery match: its smallest verified 25 mg unit is two to four times the usual 6.25-12.5 mg feline dose. Do not treat incidental asymptomatic HCM routinely or improvise an unmeasured powder fraction.

Regulatory and scientific credibility6.0/10

The exact human tablet has a sourced current Georgian registration, identifiable manufacturer, strength and verified split rule, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Clinical efficacy6.0/10

Atenolol reliably lowers heart rate and dynamic outflow velocity in selected cats, and consensus allows it for severe DLVOTO or certain arrhythmias. Evidence does not support routine asymptomatic HCM treatment: a five-year cohort found no survival benefit, and the guideline rates key recommendations as low-level evidence.

Safety and tolerability6.0/10

Predictable beta blockade is clinically useful but can cause bradycardia, hypotension, AV block, exercise intolerance or worsening low-output and decompensated heart failure. These exact human tablets lack target-animal safety dossiers; renal clearance, bronchospasm risk, metabolic masking and interacting cardiac drugs require selection and monitoring.

Clinical practicality1.0/10

The usual sourced feline dose is 6.25-12.5 mg per cat, but the smallest verified unit from this presentation is 25 mg. Crushing does not make informal powder division accurate; a lower-strength or validated patient-specific compound is normally required.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in clinically important sinus bradycardia, sick-sinus syndrome or second- or third-degree AV block without pacing; confirm rhythm before treatment.
  • Do not initiate during cardiogenic shock, acute decompensated heart failure or other unstable low-output states. Stabilise first and use only after an individual haemodynamic assessment.
  • Diltiazem, verapamil, digoxin, amiodarone, sotalol and other rate-slowing or negative-inotropic drugs can add bradycardia, AV block, hypotension or contractility depression; combine only with ECG and haemodynamic oversight.
  • Atenolol is substantially renally eliminated. Review kidney function, hydration and concurrent renally cleared drugs, and reconsider dose or interval if clearance is reduced.
  • Beta-1 selectivity is not absolute. Use cautiously in bronchospastic disease and monitor for new cough, wheeze or respiratory effort, especially at higher exposure.
  • Beta blockade may mask tachycardia from hypoglycaemia or hyperthyroidism and can alter insulin response. Monitor vulnerable diabetic, fasting, neonatal or endocrine patients rather than relying on heart rate alone.
  • Start low, titrate to the documented rhythm or haemodynamic target, and monitor pulse, blood pressure, ECG, perfusion, exercise tolerance and heart-failure signs. Do not stop chronic treatment abruptly; taper under veterinary direction.
  • This exact 50 mg tablet is verified only to a 25 mg half. Do not estimate a smaller dog or feline dose from an unmeasured fraction of crushed powder; use an accurately measurable lower strength or validated patient-specific compound.
Assessment sources
  1. Atenolol market audit2026
  2. FDA 20242024
  3. MSD Vet Manual 20242024
  4. ACVIM 20182018
  5. ACVIM feline cardiomyopathy2020
  6. Feline HCM five-year outcome2013
  7. Feline HCM physiologic response2015
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Atenolol50 mg
Formulation Type
Tablet
Administration route
By mouth
Registration
Georgia Yes, human
In force until 26 Mar 2029
Human (Ministry of Health, RAMA)
In the register: ატენოლოლი ბორისოვი 50 მგ, აბი
№ რ-040566
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Atenolol Gama 25 mg, Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label oral atenolol as veterinary-selected beta-1 blockade for selected canine tachyarrhythmias or clinically important sympathetic rate control
6.1/10
Situational / acceptable
vetman assessment

Atenolol Gama

25 mg, tablet, human medicine
Assessed clinical scopeDog · Off-label oral atenolol as veterinary-selected beta-1 blockade for selected canine tachyarrhythmias or clinically important sympathetic rate control · By mouth
Care settingSpecialist-guided or closely monitored outpatient cardiac treatment after ECG, blood pressure and haemodynamic assessment, with slow titration and scheduled reassessment
vetman score 6.1/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-035254 · Verified on 16 Oct 2026 Off-label use

A situational canine beta-1 blocker with recognised rate-control use and important disease-specific evidence limits. This whole-only 25 mg form can suit selected medium or large dogs, but not small dogs or fine titration; confirm the rhythm and haemodynamic goal and monitor response.

Regulatory and scientific credibility6.0/10

The exact human tablet has a sourced current Georgian registration, identifiable manufacturer, strength and verified split rule, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Clinical efficacy6.5/10

Atenolol produces measurable beta-1 blockade and remains a recognised veterinary class-II option, but effect depends on disease and regimen. A randomized Boxer trial found atenolol alone ineffective while mexiletine-atenolol helped; severe subaortic-stenosis cohorts found no survival benefit, and controlled pharmacodynamics support dosing more often than once daily for sustained blockade.

Safety and tolerability6.0/10

Predictable beta blockade is clinically useful but can cause bradycardia, hypotension, AV block, exercise intolerance or worsening low-output and decompensated heart failure. These exact human tablets lack target-animal safety dossiers; renal clearance, bronchospasm risk, metabolic masking and interacting cardiac drugs require selection and monitoring.

Clinical practicality5.5/10

This whole-only 25 mg tablet fits selected medium or large dogs within the broad weight-based range, but it cannot support smaller doses or fine titration. Twice-daily treatment and pulse, blood-pressure and ECG reassessment add a meaningful but manageable burden.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in clinically important sinus bradycardia, sick-sinus syndrome or second- or third-degree AV block without pacing; confirm rhythm before treatment.
  • Do not initiate during cardiogenic shock, acute decompensated heart failure or other unstable low-output states. Stabilise first and use only after an individual haemodynamic assessment.
  • Diltiazem, verapamil, digoxin, amiodarone, sotalol and other rate-slowing or negative-inotropic drugs can add bradycardia, AV block, hypotension or contractility depression; combine only with ECG and haemodynamic oversight.
  • Atenolol is substantially renally eliminated. Review kidney function, hydration and concurrent renally cleared drugs, and reconsider dose or interval if clearance is reduced.
  • Beta-1 selectivity is not absolute. Use cautiously in bronchospastic disease and monitor for new cough, wheeze or respiratory effort, especially at higher exposure.
  • Beta blockade may mask tachycardia from hypoglycaemia or hyperthyroidism and can alter insulin response. Monitor vulnerable diabetic, fasting, neonatal or endocrine patients rather than relying on heart rate alone.
  • Start low, titrate to the documented rhythm or haemodynamic target, and monitor pulse, blood pressure, ECG, perfusion, exercise tolerance and heart-failure signs. Do not stop chronic treatment abruptly; taper under veterinary direction.
  • This exact 25 mg tablet is recorded as whole-only. Do not estimate a smaller dog or feline dose from an unmeasured fraction of crushed powder; use an accurately measurable lower strength or validated patient-specific compound.
Assessment sources
  1. Atenolol market audit2026
  2. FDA 20242024
  3. MSD Vet Manual 20242024
  4. ACVIM 20182018
  5. Canine atenolol duration RCT2019
  6. Boxer antiarrhythmic RCT2002
  7. Canine subaortic stenosis outcome2014
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label oral atenolol for selected feline tachyarrhythmias or severe dynamic left-ventricular outflow obstruction; not routine treatment of asymptomatic HCM
5.2/10
Weak evidence support
vetman assessment

Atenolol Gama

25 mg, tablet, human medicine
Assessed clinical scopeCat · Off-label oral atenolol for selected feline tachyarrhythmias or severe dynamic left-ventricular outflow obstruction; not routine treatment of asymptomatic HCM · By mouth
Care settingSpecialist-guided or closely monitored outpatient cardiac treatment after ECG, blood pressure and haemodynamic assessment, with slow titration and scheduled reassessment
vetman score 5.2/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-035254 · Verified on 16 Oct 2026 Off-label use

The ingredient has a selective feline role, but this human tablet is a poor dose-delivery match: its smallest verified 25 mg unit is two to four times the usual 6.25-12.5 mg feline dose. Do not treat incidental asymptomatic HCM routinely or improvise an unmeasured powder fraction.

Regulatory and scientific credibility6.0/10

The exact human tablet has a sourced current Georgian registration, identifiable manufacturer, strength and verified split rule, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Clinical efficacy6.0/10

Atenolol reliably lowers heart rate and dynamic outflow velocity in selected cats, and consensus allows it for severe DLVOTO or certain arrhythmias. Evidence does not support routine asymptomatic HCM treatment: a five-year cohort found no survival benefit, and the guideline rates key recommendations as low-level evidence.

Safety and tolerability6.0/10

Predictable beta blockade is clinically useful but can cause bradycardia, hypotension, AV block, exercise intolerance or worsening low-output and decompensated heart failure. These exact human tablets lack target-animal safety dossiers; renal clearance, bronchospasm risk, metabolic masking and interacting cardiac drugs require selection and monitoring.

Clinical practicality1.0/10

The usual sourced feline dose is 6.25-12.5 mg per cat, but the smallest verified unit from this presentation is 25 mg. Crushing does not make informal powder division accurate; a lower-strength or validated patient-specific compound is normally required.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in clinically important sinus bradycardia, sick-sinus syndrome or second- or third-degree AV block without pacing; confirm rhythm before treatment.
  • Do not initiate during cardiogenic shock, acute decompensated heart failure or other unstable low-output states. Stabilise first and use only after an individual haemodynamic assessment.
  • Diltiazem, verapamil, digoxin, amiodarone, sotalol and other rate-slowing or negative-inotropic drugs can add bradycardia, AV block, hypotension or contractility depression; combine only with ECG and haemodynamic oversight.
  • Atenolol is substantially renally eliminated. Review kidney function, hydration and concurrent renally cleared drugs, and reconsider dose or interval if clearance is reduced.
  • Beta-1 selectivity is not absolute. Use cautiously in bronchospastic disease and monitor for new cough, wheeze or respiratory effort, especially at higher exposure.
  • Beta blockade may mask tachycardia from hypoglycaemia or hyperthyroidism and can alter insulin response. Monitor vulnerable diabetic, fasting, neonatal or endocrine patients rather than relying on heart rate alone.
  • Start low, titrate to the documented rhythm or haemodynamic target, and monitor pulse, blood pressure, ECG, perfusion, exercise tolerance and heart-failure signs. Do not stop chronic treatment abruptly; taper under veterinary direction.
  • This exact 25 mg tablet is recorded as whole-only. Do not estimate a smaller dog or feline dose from an unmeasured fraction of crushed powder; use an accurately measurable lower strength or validated patient-specific compound.
Assessment sources
  1. Atenolol market audit2026
  2. FDA 20242024
  3. MSD Vet Manual 20242024
  4. ACVIM 20182018
  5. ACVIM feline cardiomyopathy2020
  6. Feline HCM five-year outcome2013
  7. Feline HCM physiologic response2015
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Atenolol25 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
GAMA
Registration
Georgia Yes, human
In force until 18 May 2027
Human (Ministry of Health, RAMA)
In the register: ატენოლოლი გამა 25 მგ, აბი
№ რ-035254
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Atenolol Sopharma 25 mg, Tablet

film-coated tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label oral atenolol as veterinary-selected beta-1 blockade for selected canine tachyarrhythmias or clinically important sympathetic rate control
6.2/10
Situational / acceptable
vetman assessment

Atenolol Sopharma

25 mg, film-coated tablet, human medicine
Assessed clinical scopeDog · Off-label oral atenolol as veterinary-selected beta-1 blockade for selected canine tachyarrhythmias or clinically important sympathetic rate control · By mouth
Care settingSpecialist-guided or closely monitored outpatient cardiac treatment after ECG, blood pressure and haemodynamic assessment, with slow titration and scheduled reassessment
vetman score 6.2/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-035479 · Verified on 16 Oct 2026 Off-label use

A situational canine beta-1 blocker with recognised rate-control use and important disease-specific evidence limits. This whole-only 25 mg form can suit selected medium or large dogs, but not small dogs or fine titration; confirm the rhythm and haemodynamic goal and monitor response.

Regulatory and scientific credibility6.5/10

The exact human tablet has sourced current registrations in Georgia and EU/EEA, with an identifiable manufacturer, strength and verified split rule. It has no veterinary authorisation, no checked UK or US exact trade-name registration, and animal use is off-label.

Clinical efficacy6.5/10

Atenolol produces measurable beta-1 blockade and remains a recognised veterinary class-II option, but effect depends on disease and regimen. A randomized Boxer trial found atenolol alone ineffective while mexiletine-atenolol helped; severe subaortic-stenosis cohorts found no survival benefit, and controlled pharmacodynamics support dosing more often than once daily for sustained blockade.

Safety and tolerability6.0/10

Predictable beta blockade is clinically useful but can cause bradycardia, hypotension, AV block, exercise intolerance or worsening low-output and decompensated heart failure. These exact human tablets lack target-animal safety dossiers; renal clearance, bronchospasm risk, metabolic masking and interacting cardiac drugs require selection and monitoring.

Clinical practicality5.5/10

This whole-only 25 mg tablet fits selected medium or large dogs within the broad weight-based range, but it cannot support smaller doses or fine titration. Twice-daily treatment and pulse, blood-pressure and ECG reassessment add a meaningful but manageable burden.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in clinically important sinus bradycardia, sick-sinus syndrome or second- or third-degree AV block without pacing; confirm rhythm before treatment.
  • Do not initiate during cardiogenic shock, acute decompensated heart failure or other unstable low-output states. Stabilise first and use only after an individual haemodynamic assessment.
  • Diltiazem, verapamil, digoxin, amiodarone, sotalol and other rate-slowing or negative-inotropic drugs can add bradycardia, AV block, hypotension or contractility depression; combine only with ECG and haemodynamic oversight.
  • Atenolol is substantially renally eliminated. Review kidney function, hydration and concurrent renally cleared drugs, and reconsider dose or interval if clearance is reduced.
  • Beta-1 selectivity is not absolute. Use cautiously in bronchospastic disease and monitor for new cough, wheeze or respiratory effort, especially at higher exposure.
  • Beta blockade may mask tachycardia from hypoglycaemia or hyperthyroidism and can alter insulin response. Monitor vulnerable diabetic, fasting, neonatal or endocrine patients rather than relying on heart rate alone.
  • Start low, titrate to the documented rhythm or haemodynamic target, and monitor pulse, blood pressure, ECG, perfusion, exercise tolerance and heart-failure signs. Do not stop chronic treatment abruptly; taper under veterinary direction.
  • This exact 25 mg tablet is recorded as whole-only. Do not estimate a smaller dog or feline dose from an unmeasured fraction of crushed powder; use an accurately measurable lower strength or validated patient-specific compound.
Assessment sources
  1. Atenolol market audit2026
  2. FDA 20242024
  3. MSD Vet Manual 20242024
  4. ACVIM 20182018
  5. Canine atenolol duration RCT2019
  6. Boxer antiarrhythmic RCT2002
  7. Canine subaortic stenosis outcome2014
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label oral atenolol for selected feline tachyarrhythmias or severe dynamic left-ventricular outflow obstruction; not routine treatment of asymptomatic HCM
5.3/10
Weak evidence support
vetman assessment

Atenolol Sopharma

25 mg, film-coated tablet, human medicine
Assessed clinical scopeCat · Off-label oral atenolol for selected feline tachyarrhythmias or severe dynamic left-ventricular outflow obstruction; not routine treatment of asymptomatic HCM · By mouth
Care settingSpecialist-guided or closely monitored outpatient cardiac treatment after ECG, blood pressure and haemodynamic assessment, with slow titration and scheduled reassessment
vetman score 5.3/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-035479 · Verified on 16 Oct 2026 Off-label use

The ingredient has a selective feline role, but this human tablet is a poor dose-delivery match: its smallest verified 25 mg unit is two to four times the usual 6.25-12.5 mg feline dose. Do not treat incidental asymptomatic HCM routinely or improvise an unmeasured powder fraction.

Regulatory and scientific credibility6.5/10

The exact human tablet has sourced current registrations in Georgia and EU/EEA, with an identifiable manufacturer, strength and verified split rule. It has no veterinary authorisation, no checked UK or US exact trade-name registration, and animal use is off-label.

Clinical efficacy6.0/10

Atenolol reliably lowers heart rate and dynamic outflow velocity in selected cats, and consensus allows it for severe DLVOTO or certain arrhythmias. Evidence does not support routine asymptomatic HCM treatment: a five-year cohort found no survival benefit, and the guideline rates key recommendations as low-level evidence.

Safety and tolerability6.0/10

Predictable beta blockade is clinically useful but can cause bradycardia, hypotension, AV block, exercise intolerance or worsening low-output and decompensated heart failure. These exact human tablets lack target-animal safety dossiers; renal clearance, bronchospasm risk, metabolic masking and interacting cardiac drugs require selection and monitoring.

Clinical practicality1.0/10

The usual sourced feline dose is 6.25-12.5 mg per cat, but the smallest verified unit from this presentation is 25 mg. Crushing does not make informal powder division accurate; a lower-strength or validated patient-specific compound is normally required.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in clinically important sinus bradycardia, sick-sinus syndrome or second- or third-degree AV block without pacing; confirm rhythm before treatment.
  • Do not initiate during cardiogenic shock, acute decompensated heart failure or other unstable low-output states. Stabilise first and use only after an individual haemodynamic assessment.
  • Diltiazem, verapamil, digoxin, amiodarone, sotalol and other rate-slowing or negative-inotropic drugs can add bradycardia, AV block, hypotension or contractility depression; combine only with ECG and haemodynamic oversight.
  • Atenolol is substantially renally eliminated. Review kidney function, hydration and concurrent renally cleared drugs, and reconsider dose or interval if clearance is reduced.
  • Beta-1 selectivity is not absolute. Use cautiously in bronchospastic disease and monitor for new cough, wheeze or respiratory effort, especially at higher exposure.
  • Beta blockade may mask tachycardia from hypoglycaemia or hyperthyroidism and can alter insulin response. Monitor vulnerable diabetic, fasting, neonatal or endocrine patients rather than relying on heart rate alone.
  • Start low, titrate to the documented rhythm or haemodynamic target, and monitor pulse, blood pressure, ECG, perfusion, exercise tolerance and heart-failure signs. Do not stop chronic treatment abruptly; taper under veterinary direction.
  • This exact 25 mg tablet is recorded as whole-only. Do not estimate a smaller dog or feline dose from an unmeasured fraction of crushed powder; use an accurately measurable lower strength or validated patient-specific compound.
Assessment sources
  1. Atenolol market audit2026
  2. FDA 20242024
  3. MSD Vet Manual 20242024
  4. ACVIM 20182018
  5. ACVIM feline cardiomyopathy2020
  6. Feline HCM five-year outcome2013
  7. Feline HCM physiologic response2015
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Atenolol25 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Sopharma · Bulgaria
Registration
Georgia Yes, human
In force until 07 Jun 2027
Human (Ministry of Health, RAMA)
In the register: ატენოლოლი სოფარმა 25 მგ, აბი
№ რ-035479
Verified on: 16 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Atenolol Sopharma 50 mg, Tablet

film-coated tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label oral atenolol as veterinary-selected beta-1 blockade for selected canine tachyarrhythmias or clinically important sympathetic rate control
6.3/10
Situational / acceptable
vetman assessment

Atenolol Sopharma

50 mg, film-coated tablet, human medicine
Assessed clinical scopeDog · Off-label oral atenolol as veterinary-selected beta-1 blockade for selected canine tachyarrhythmias or clinically important sympathetic rate control · By mouth
Care settingSpecialist-guided or closely monitored outpatient cardiac treatment after ECG, blood pressure and haemodynamic assessment, with slow titration and scheduled reassessment
vetman score 6.3/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-035480 · Verified on 16 Oct 2026 Off-label use

A situational canine beta-1 blocker with recognised rate-control use and important disease-specific evidence limits. Verified 25 and 50 mg units are workable for selected medium or large dogs, but smaller or fine-titrated doses require a more suitable formulation.

Regulatory and scientific credibility6.5/10

The exact human tablet has sourced current registrations in Georgia and EU/EEA, with an identifiable manufacturer, strength and verified split rule. It has no veterinary authorisation, no checked UK or US exact trade-name registration, and animal use is off-label.

Clinical efficacy6.5/10

Atenolol produces measurable beta-1 blockade and remains a recognised veterinary class-II option, but effect depends on disease and regimen. A randomized Boxer trial found atenolol alone ineffective while mexiletine-atenolol helped; severe subaortic-stenosis cohorts found no survival benefit, and controlled pharmacodynamics support dosing more often than once daily for sustained blockade.

Safety and tolerability6.0/10

Predictable beta blockade is clinically useful but can cause bradycardia, hypotension, AV block, exercise intolerance or worsening low-output and decompensated heart failure. These exact human tablets lack target-animal safety dossiers; renal clearance, bronchospasm risk, metabolic masking and interacting cardiac drugs require selection and monitoring.

Clinical practicality6.0/10

The scored 50 mg tablet provides verified 25 mg or 50 mg units, covering selected medium and large dogs better than a whole-only presentation. It still cannot support small-dog or fine dose adjustment, and twice-daily monitored titration remains necessary.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in clinically important sinus bradycardia, sick-sinus syndrome or second- or third-degree AV block without pacing; confirm rhythm before treatment.
  • Do not initiate during cardiogenic shock, acute decompensated heart failure or other unstable low-output states. Stabilise first and use only after an individual haemodynamic assessment.
  • Diltiazem, verapamil, digoxin, amiodarone, sotalol and other rate-slowing or negative-inotropic drugs can add bradycardia, AV block, hypotension or contractility depression; combine only with ECG and haemodynamic oversight.
  • Atenolol is substantially renally eliminated. Review kidney function, hydration and concurrent renally cleared drugs, and reconsider dose or interval if clearance is reduced.
  • Beta-1 selectivity is not absolute. Use cautiously in bronchospastic disease and monitor for new cough, wheeze or respiratory effort, especially at higher exposure.
  • Beta blockade may mask tachycardia from hypoglycaemia or hyperthyroidism and can alter insulin response. Monitor vulnerable diabetic, fasting, neonatal or endocrine patients rather than relying on heart rate alone.
  • Start low, titrate to the documented rhythm or haemodynamic target, and monitor pulse, blood pressure, ECG, perfusion, exercise tolerance and heart-failure signs. Do not stop chronic treatment abruptly; taper under veterinary direction.
  • This exact 50 mg tablet is verified only to a 25 mg half. Do not estimate a smaller dog or feline dose from an unmeasured fraction of crushed powder; use an accurately measurable lower strength or validated patient-specific compound.
Assessment sources
  1. Atenolol market audit2026
  2. FDA 20242024
  3. MSD Vet Manual 20242024
  4. ACVIM 20182018
  5. Canine atenolol duration RCT2019
  6. Boxer antiarrhythmic RCT2002
  7. Canine subaortic stenosis outcome2014
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label oral atenolol for selected feline tachyarrhythmias or severe dynamic left-ventricular outflow obstruction; not routine treatment of asymptomatic HCM
5.3/10
Weak evidence support
vetman assessment

Atenolol Sopharma

50 mg, film-coated tablet, human medicine
Assessed clinical scopeCat · Off-label oral atenolol for selected feline tachyarrhythmias or severe dynamic left-ventricular outflow obstruction; not routine treatment of asymptomatic HCM · By mouth
Care settingSpecialist-guided or closely monitored outpatient cardiac treatment after ECG, blood pressure and haemodynamic assessment, with slow titration and scheduled reassessment
vetman score 5.3/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-035480 · Verified on 16 Oct 2026 Off-label use

The ingredient has a selective feline role, but this human tablet is a poor dose-delivery match: its smallest verified 25 mg unit is two to four times the usual 6.25-12.5 mg feline dose. Do not treat incidental asymptomatic HCM routinely or improvise an unmeasured powder fraction.

Regulatory and scientific credibility6.5/10

The exact human tablet has sourced current registrations in Georgia and EU/EEA, with an identifiable manufacturer, strength and verified split rule. It has no veterinary authorisation, no checked UK or US exact trade-name registration, and animal use is off-label.

Clinical efficacy6.0/10

Atenolol reliably lowers heart rate and dynamic outflow velocity in selected cats, and consensus allows it for severe DLVOTO or certain arrhythmias. Evidence does not support routine asymptomatic HCM treatment: a five-year cohort found no survival benefit, and the guideline rates key recommendations as low-level evidence.

Safety and tolerability6.0/10

Predictable beta blockade is clinically useful but can cause bradycardia, hypotension, AV block, exercise intolerance or worsening low-output and decompensated heart failure. These exact human tablets lack target-animal safety dossiers; renal clearance, bronchospasm risk, metabolic masking and interacting cardiac drugs require selection and monitoring.

Clinical practicality1.0/10

The usual sourced feline dose is 6.25-12.5 mg per cat, but the smallest verified unit from this presentation is 25 mg. Crushing does not make informal powder division accurate; a lower-strength or validated patient-specific compound is normally required.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in clinically important sinus bradycardia, sick-sinus syndrome or second- or third-degree AV block without pacing; confirm rhythm before treatment.
  • Do not initiate during cardiogenic shock, acute decompensated heart failure or other unstable low-output states. Stabilise first and use only after an individual haemodynamic assessment.
  • Diltiazem, verapamil, digoxin, amiodarone, sotalol and other rate-slowing or negative-inotropic drugs can add bradycardia, AV block, hypotension or contractility depression; combine only with ECG and haemodynamic oversight.
  • Atenolol is substantially renally eliminated. Review kidney function, hydration and concurrent renally cleared drugs, and reconsider dose or interval if clearance is reduced.
  • Beta-1 selectivity is not absolute. Use cautiously in bronchospastic disease and monitor for new cough, wheeze or respiratory effort, especially at higher exposure.
  • Beta blockade may mask tachycardia from hypoglycaemia or hyperthyroidism and can alter insulin response. Monitor vulnerable diabetic, fasting, neonatal or endocrine patients rather than relying on heart rate alone.
  • Start low, titrate to the documented rhythm or haemodynamic target, and monitor pulse, blood pressure, ECG, perfusion, exercise tolerance and heart-failure signs. Do not stop chronic treatment abruptly; taper under veterinary direction.
  • This exact 50 mg tablet is verified only to a 25 mg half. Do not estimate a smaller dog or feline dose from an unmeasured fraction of crushed powder; use an accurately measurable lower strength or validated patient-specific compound.
Assessment sources
  1. Atenolol market audit2026
  2. FDA 20242024
  3. MSD Vet Manual 20242024
  4. ACVIM 20182018
  5. ACVIM feline cardiomyopathy2020
  6. Feline HCM five-year outcome2013
  7. Feline HCM physiologic response2015
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Atenolol50 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Sopharma · Bulgaria
Registration
Georgia Yes, human
In force until 07 Jun 2027
Human (Ministry of Health, RAMA)
In the register: ატენოლოლი სოფარმა 50 მგ, აბი
№ რ-035480
Verified on: 16 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗